Equities
  • Price (HKD)1.47
  • Today's Change-0.08 / -5.16%
  • Shares traded8.71m
  • 1 Year change-25.76%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in CNYView more

In 2023, CStone Pharmaceuticals increased its cash reserves by 78.40%, or 437.99m. Cash Flow from Investing totalled 619.61m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 588.84m for operations while cash generated from financing totalled 388.36m.
Cash flow per share-0.0766
Price/Cash flow per share--
Book value per share0.4008
Tangible book value per share0.2575
More ▼

Balance sheet in CNYView more

CStone Pharmaceuticals has a Debt to Total Capital ratio of 41.71%, a higher figure than the previous year's 29.44%.
Current ratio1.71
Quick ratio1.45
Total debt/total equity0.7156
Total debt/total capital0.4171
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.